{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:22:33Z","timestamp":1792005753438,"version":"4.4.0"},"reference-count":153,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1213\/ane.0b013e31819bcc9c","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T17:35:09Z","timestamp":1242927309000},"page":"1433-1446","source":"Crossref","is-referenced-by-count":289,"title":["Blood Coagulation: Hemostasis and Thrombin Regulation"],"prefix":"10.1213","volume":"108","author":[{"given":"Kenichi A.","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210902","doi-asserted-by":"crossref","first-page":"50819","DOI":"10.1074\/jbc.X300009200","article-title":"A brief historical review of the waterfall\/cascade of blood coagulation.","volume":"278","author":"Davie","year":"2003","journal-title":"J Biol Chem"},{"key":"R2-13-20210902","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis.","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"R3-13-20210902","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0092-8674(85)80046-5","article-title":"Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules.","volume":"41","author":"Patthy","year":"1985","journal-title":"Cell"},{"key":"R4-13-20210902","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-0037-1614222","article-title":"Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss\u2014a possible evolutionary selection mechanism.","volume":"79","author":"Lindqvist","year":"1998","journal-title":"Thromb Haemost"},{"key":"R5-13-20210902","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1093\/emboj\/20.12.3036","article-title":"Molecular markers of serine protease evolution.","volume":"20","author":"Krem","year":"2001","journal-title":"EMBO J"},{"key":"R6-13-20210902","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1046\/j.1538-7836.2003.00334.x","article-title":"450 million years of hemostasis.","volume":"1","author":"Davidson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R7-13-20210902","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.it.2004.03.004","article-title":"Coagulation in arthropods: defence, wound closure and healing.","volume":"25","author":"Theopold","year":"2004","journal-title":"Trends Immunol"},{"key":"R8-13-20210902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.jbchem.a021894","article-title":"New types of clotting factors and defense molecules found in horseshoe crab hemolymph: their structures and functions.","volume":"123","author":"Iwanaga","year":"1998","journal-title":"J Biochem"},{"key":"R9-13-20210902","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","article-title":"Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.","volume":"273","author":"Baugh","year":"1998","journal-title":"J Biol Chem"},{"key":"R10-13-20210902","doi-asserted-by":"crossref","first-page":"17241","DOI":"10.1074\/jbc.M312827200","article-title":"Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III.","volume":"279","author":"Lu","year":"2004","journal-title":"J Biol Chem"},{"key":"R11-13-20210902","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-0037-1615853","article-title":"Protease-activated receptors and platelet function.","volume":"82","author":"Coughlin","year":"1999","journal-title":"Thromb Haemost"},{"key":"R12-13-20210902","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1182\/blood-2005-04-1710","article-title":"Directing thrombin.","volume":"106","author":"Lane","year":"2005","journal-title":"Blood"},{"key":"R13-13-20210902","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.1016\/S0021-9258(17)44879-4","article-title":"Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin.","volume":"265","author":"Monkovic","year":"1990","journal-title":"J Biol Chem"},{"key":"R14-13-20210902","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.1652157","article-title":"Factor XI activation in a revised model of blood coagulation.","volume":"253","author":"Gailani","year":"1991","journal-title":"Science"},{"key":"R15-13-20210902","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/01.ATV.0000128125.80559.9c","article-title":"Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available.","volume":"24","author":"Wielders","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-13-20210902","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"key":"R17-13-20210902","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1213\/ane.0b013e3181618702","article-title":"Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.","volume":"106","author":"Szlam","year":"2008","journal-title":"Anesth Analg"},{"key":"R18-13-20210902","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood.V55.5.841.841","article-title":"Correlation between fibrinogen binding to human platelets and platelet aggregability.","volume":"55","author":"Peerschke","year":"1980","journal-title":"Blood"},{"key":"R19-13-20210902","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1021\/bi00117a017","article-title":"Interactions of factor XIII with fibrin as substrate and cofactor.","volume":"31","author":"Hornyak","year":"1992","journal-title":"Biochemistry"},{"key":"R20-13-20210902","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI9896","article-title":"Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.","volume":"106","author":"Ni","year":"2000","journal-title":"J Clin Invest"},{"key":"R21-13-20210902","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.jvca.2004.11.021","article-title":"Case 1\u20132005: cardiac surgery in congenital afibrinogenemia with thrombo-occlusive disease.","volume":"19","author":"Chun","year":"2005","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R22-13-20210902","first-page":"214","article-title":"A history of blood coagulation.","author":"Owen","year":"2001"},{"key":"R23-13-20210902","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/ALN.0b013e3181895bd8","article-title":"Perioperative hemostatic management of patients treated with vitamin K antagonists.","volume":"109","author":"Levy","year":"2008","journal-title":"Anesthesiology"},{"key":"R24-13-20210902","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/hep.21732","article-title":"How to implement the modified international normalized ratio for cirrhosis (INR liver) for model for end-stage liver disease calculation.","volume":"46","author":"Tripodi","year":"2007","journal-title":"Hepatology"},{"key":"R25-13-20210902","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1046\/j.1538-7836.2003.00459.x","article-title":"The partial thromboplastin time: defining an era in coagulation.","volume":"1","author":"White","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R26-13-20210902","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1042\/bj2430579","article-title":"The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin.","volume":"243","author":"Ofosu","year":"1987","journal-title":"Biochem J"},{"key":"R27-13-20210902","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1046\/j.1538-7836.2003.00127.x","article-title":"Predicting the pharmacology of thrombin inhibitors.","volume":"1","author":"Adams","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R28-13-20210902","first-page":"13","article-title":"Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients.","volume":"82","author":"Despotis","year":"1996","journal-title":"Anesth Analg"},{"key":"R29-13-20210902","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.lab.2005.12.007","article-title":"Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery.","volume":"147","author":"Carroll","year":"2006","journal-title":"J Lab Clin Med"},{"key":"R30-13-20210902","first-page":"179","article-title":"A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency.","volume":"5","author":"Duckert","year":"1960","journal-title":"Thromb Diath Haemorrh"},{"key":"R31-13-20210902","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI109387","article-title":"Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency.","volume":"63","author":"Aoki","year":"1979","journal-title":"J Clin Invest"},{"key":"R32-13-20210902","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","article-title":"Platelet function monitoring in patients with coronary artery disease.","volume":"50","author":"Gurbel","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R33-13-20210902","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1213\/ane.0b013e318168b367","article-title":"Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices.","volume":"106","author":"Ganter","year":"2008","journal-title":"Anesth Analg"},{"key":"R34-13-20210902","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2007.09.003","article-title":"Beyond cell based models of coagulation: analyses of coagulation with clot \u201clifespan\u201d resistance-time relationships.","volume":"122","author":"Nielsen","year":"2008","journal-title":"Thromb Res"},{"key":"R35-13-20210902","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1538-7836.2006.01959.x","article-title":"Human endothelial cells synthesize and release ADAMTS-13.","volume":"4","author":"Turner","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R36-13-20210902","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1025377206600","article-title":"Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.","volume":"19","author":"Shworak","year":"2002","journal-title":"Glycoconj J"},{"key":"R37-13-20210902","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI109736","article-title":"Human pulmonary endothelial cells in culture. Activities of cells from arteries and cells from veins.","volume":"65","author":"Johnson","year":"1980","journal-title":"J Clin Invest"},{"key":"R38-13-20210902","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1055\/s-0038-1653884","article-title":"Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH.","volume":"73","author":"Osterud","year":"1995","journal-title":"Thromb Haemost"},{"key":"R39-13-20210902","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood.V67.2.362.362","article-title":"Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.","volume":"67","author":"Ishii","year":"1986","journal-title":"Blood"},{"key":"R40-13-20210902","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V92.8.2791","article-title":"Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo.","volume":"92","author":"Yamamoto","year":"1998","journal-title":"Blood"},{"key":"R41-13-20210902","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1538-7836.2005.01328.x","article-title":"Spatial and temporal dynamics of the endothelium.","volume":"3","author":"Aird","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R42-13-20210902","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.ATV.20.3.874","article-title":"Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor.","volume":"20","author":"Ott","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R43-13-20210902","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0049-3848(88)90340-4","article-title":"Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).","volume":"50","author":"Sandset","year":"1988","journal-title":"Thromb Res"},{"key":"R44-13-20210902","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.111.3.1293","article-title":"Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta.","volume":"111","author":"de Agostini","year":"1990","journal-title":"J Cell Biol"},{"key":"R45-13-20210902","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1749-6632.1992.tb51622.x","article-title":"Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products.","volume":"667","author":"Emeis","year":"1992","journal-title":"Ann NY Acad Sci"},{"key":"R46-13-20210902","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood.V79.7.1720.1720","article-title":"Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.","volume":"79","author":"Taylor","year":"1992","journal-title":"Blood"},{"key":"R47-13-20210902","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00003246-200107001-00013","article-title":"Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis.","volume":"29","author":"Aird","year":"2001","journal-title":"Crit Care Med"},{"key":"R48-13-20210902","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood.V85.11.3144.bloodjournal85113144","article-title":"Hypercoagulability in centenarians: the paradox of successful aging.","volume":"85","author":"Mari","year":"1995","journal-title":"Blood"},{"key":"R49-13-20210902","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tmrv.2004.03.003","article-title":"Relationship between platelet count and bleeding risk in thrombocytopenic patients.","volume":"18","author":"Slichter","year":"2004","journal-title":"Transfus Med Rev"},{"key":"R50-13-20210902","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1538-7836.2003.00261.x","article-title":"Inflammation and thrombosis.","volume":"1","author":"Esmon","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R51-13-20210902","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26S","article-title":"The protein C pathway.","volume":"124","author":"Esmon","year":"2003","journal-title":"Chest"},{"key":"R52-13-20210902","doi-asserted-by":"crossref","first-page":"13122","DOI":"10.1074\/jbc.M410381200","article-title":"PAR1 cleavage and signaling in response to activated protein C and thrombin.","volume":"280","author":"Ludeman","year":"2005","journal-title":"J Biol Chem"},{"key":"R53-13-20210902","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway.","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"R54-13-20210902","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000236661","article-title":"Pro-carboxypeptidase R cleaves bradykinin following activation.","volume":"103","author":"Shinohara","year":"1994","journal-title":"Int Arch Allergy Immunol"},{"key":"R55-13-20210902","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1348-0421.2002.tb02669.x","article-title":"Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N.","volume":"46","author":"Campbell","year":"2002","journal-title":"Microbiol Immunol"},{"key":"R56-13-20210902","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1172\/JCI116795","article-title":"Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.","volume":"92","author":"Hanson","year":"1993","journal-title":"J Clin Invest"},{"key":"R57-13-20210902","first-page":"375","article-title":"Induction of glomerular microclot formation by fibrin monomer infusion.","volume":"29","author":"Muller-Berghaus","year":"1973","journal-title":"Thromb Diath Haemorrh"},{"key":"R58-13-20210902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2003.10.003","article-title":"von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.","volume":"41","author":"Moake","year":"2004","journal-title":"Semin Hematol"},{"key":"R59-13-20210902","first-page":"360","article-title":"Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates.","volume":"81","author":"Hiippala","year":"1995","journal-title":"Anesth Analg"},{"key":"R60-13-20210902","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/bja\/85.3.487","article-title":"Management of massive blood loss: a template guideline.","volume":"85","author":"Stainsby","year":"2000","journal-title":"Br J Anaesth"},{"key":"R61-13-20210902","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2003-12-4352","article-title":"Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa.","volume":"104","author":"Hathcock","year":"2004","journal-title":"Blood"},{"key":"R62-13-20210902","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1160\/TH07-04-0274","article-title":"Update on antithrombin I (fibrin).","volume":"98","author":"Mosesson","year":"2007","journal-title":"Thromb Haemost"},{"key":"R63-13-20210902","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/01.sla.0000256862.79374.31","article-title":"Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?","volume":"245","author":"Brohi","year":"2007","journal-title":"Ann Surg"},{"key":"R64-13-20210902","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MBC.0b013e3282f40d4a","article-title":"Reduced levels of fibrin (Antithrombin I) and anithrombin III underlie coagulopathy following complex cardiac surgery","volume":"19","author":"Sniecinski","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R65-13-20210902","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1213\/01.ANE.0000134800.46276.21","article-title":"Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding.","volume":"99","author":"Wettstein","year":"2004","journal-title":"Anesth Analg"},{"key":"R66-13-20210902","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0028-1092873","article-title":"Prohemostatic agents to prevent perioperative blood loss.","volume":"34","author":"Levy","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"R67-13-20210902","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00101-005-0865-7","article-title":"High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion.","volume":"54","author":"Heindl","year":"2005","journal-title":"Anaesthesist"},{"key":"R68-13-20210902","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-2007-1010236","article-title":"The effect of factor XIII on bleeding in coronary surgery.","volume":"46","author":"Godje","year":"1998","journal-title":"Thorac Cardiovasc Surg"},{"key":"R69-13-20210902","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1537-2995.2006.00824.x","article-title":"Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.","volume":"46","author":"Levy","year":"2006","journal-title":"Transfusion"},{"key":"R70-13-20210902","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jama.295.3.293","article-title":"Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.","volume":"295","author":"O\u2019Connell","year":"2006","journal-title":"JAMA"},{"key":"R71-13-20210902","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1213\/ane.0b013e3181608f7c","article-title":"Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass.","volume":"106","author":"Sniecinski","year":"2008","journal-title":"Anesth Analg"},{"key":"R72-13-20210902","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.jvca.2007.09.020","article-title":"Case 6\u20132007: massive intraoperative thrombosis and death after recombinant activated factor VII administration.","volume":"21","author":"Lichtman","year":"2007","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R73-13-20210902","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1213\/ane.0b013e31815edb52","article-title":"Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia.","volume":"106","author":"Apostolidou","year":"2008","journal-title":"Anesth Analg"},{"key":"R74-13-20210902","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1213\/01.ANE.0000130257.64006.5C","article-title":"Activation of hemostasis after coronary artery bypass grafting with or without cardiopulmonary bypass.","volume":"99","author":"Lo","year":"2004","journal-title":"Anesth Analg"},{"key":"R75-13-20210902","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jtcvs.2005.07.049","article-title":"The role of tissue factor and P-selectin in the procoagulant response that occurs in the first month after on-pump and off-pump coronary artery bypass grafting.","volume":"130","author":"Parolari","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R76-13-20210902","doi-asserted-by":"crossref","first-page":"299S","DOI":"10.1378\/chest.08-0675","article-title":"The perioperative management of antithrombotic therapy: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Douketis","year":"2008","journal-title":"Chest"},{"key":"R77-13-20210902","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/asheducation-2007.1.127","article-title":"Thrombophilia: common questions on laboratory assessment and management.","volume":"2007","author":"Heit","year":"2007","journal-title":"Hematology"},{"key":"R78-13-20210902","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/01.ATV.0000107402.79771.fc","article-title":"Genetic determinants of arterial thrombosis.","volume":"24","author":"Voetsch","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R79-13-20210902","doi-asserted-by":"crossref","first-page":"104B","DOI":"10.1016\/S0735-1097(86)80012-2","article-title":"Epidemiology and pathogenesis of venous thrombosis.","volume":"8","author":"Hirsh","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R80-13-20210902","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state.","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"key":"R81-13-20210902","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease.","volume":"340","author":"Ross","year":"1999","journal-title":"New Engl J Med"},{"key":"R82-13-20210902","first-page":"795","article-title":"Hemostasis and thrombosis. 5\/e Ed.","author":"Libby","year":"2006"},{"key":"R83-13-20210902","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/asheducation-2006.1.438","article-title":"Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms.","volume":"2006","author":"Lee","year":"2006","journal-title":"Hematology"},{"key":"R84-13-20210902","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/asheducation-2005.1.452","article-title":"Inherited risk factors for venous thrombosis.","author":"Cushman","year":"2005","journal-title":"Hematology"},{"key":"R85-13-20210902","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"R86-13-20210902","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/jaut.2000.0407","article-title":"Antiphospholipid antibodies and the protein C pathway.","volume":"15","author":"Esmon","year":"2000","journal-title":"J Autoimmun"},{"key":"R87-13-20210902","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2006.06385.x","article-title":"Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.","volume":"136","author":"Liestol","year":"2007","journal-title":"Br J Haematol"},{"key":"R88-13-20210902","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1538-7836.2003.00264.x","article-title":"Estrogens, progestogens and thrombosis.","volume":"1","author":"Rosendaal","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R89-13-20210902","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.bjp.0706153","article-title":"New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.","volume":"144","author":"Bates","year":"2005","journal-title":"Br J Pharmacol"},{"key":"R90-13-20210902","doi-asserted-by":"crossref","first-page":"454S","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"R91-13-20210902","doi-asserted-by":"crossref","first-page":"776S","DOI":"10.1378\/chest.08-0685","article-title":"The primary and secondary prevention of coronary artery disease: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Becker","year":"2008","journal-title":"Chest"},{"key":"R92-13-20210902","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ahj.2008.06.004","article-title":"Pharmacology of emerging novel platelet inhibitors.","volume":"156","author":"Angiolillo","year":"2008","journal-title":"Am Heart J"},{"key":"R93-13-20210902","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.amjcard.2004.04.050","article-title":"Time trends in warfarin-associated hemorrhage.","volume":"94","author":"Kucher","year":"2004","journal-title":"Am J Cardiol"},{"key":"R94-13-20210902","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2796.2005.01595.x","article-title":"Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation.","volume":"259","author":"Friberg","year":"2006","journal-title":"J Int Med"},{"key":"R95-13-20210902","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.V75.9.1753.1753","article-title":"Molecular basis of vitamin K-dependent gamma-carboxylation.","volume":"75","author":"Furie","year":"1990","journal-title":"Blood"},{"key":"R96-13-20210902","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1172\/JCI113475","article-title":"Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation.","volume":"81","author":"D\u2019Angelo","year":"1988","journal-title":"J Clin Invest"},{"key":"R97-13-20210902","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Int Med"},{"key":"R98-13-20210902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves.","volume":"333","author":"Cannegieter","year":"1995","journal-title":"New Engl J Med"},{"key":"R99-13-20210902","doi-asserted-by":"crossref","first-page":"429S","DOI":"10.1378\/chest.126.3_suppl.429S","article-title":"Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.","volume":"126","author":"Singer","year":"2004","journal-title":"Chest"},{"key":"R100-13-20210902","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.","volume":"345","author":"Mohr","year":"2001","journal-title":"New Engl J Med"},{"key":"R101-13-20210902","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ajh.21046","article-title":"Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.","volume":"83","author":"Leissinger","year":"2008","journal-title":"Am J Hematol"},{"key":"R102-13-20210902","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: ACCP Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R103-13-20210902","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2004.04868.x","article-title":"Efficacy of standard dose and 30 ml\/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.","volume":"125","author":"Chowdhury","year":"2004","journal-title":"Br J Haematol"},{"key":"R104-13-20210902","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.0007-1048.2001.03295.x","article-title":"Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients.","volume":"116","author":"Preston","year":"2002","journal-title":"Br J Haematol"},{"key":"R105-13-20210902","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.thromres.2005.08.005","article-title":"Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial.","volume":"118","author":"van Aart","year":"2006","journal-title":"Thromb Res"},{"key":"R106-13-20210902","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0049-3848(80)90190-5","article-title":"Some properties of antithrombin-III and its concentration in human plasma.","volume":"18","author":"Murano","year":"1980","journal-title":"Thromb Res"},{"key":"R107-13-20210902","doi-asserted-by":"crossref","first-page":"47288","DOI":"10.1074\/jbc.M408961200","article-title":"Allosteric activation of antithrombin critically depends upon hinge region extension.","volume":"279","author":"Langdown","year":"2004","journal-title":"J Biol Chem"},{"key":"R108-13-20210902","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins.","volume":"337","author":"Weitz","year":"1997","journal-title":"New Engl J Med"},{"key":"R109-13-20210902","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCULATIONAHA.106.685974","article-title":"Beyond unfractionated heparin and warfarin: current and future advances.","volume":"116","author":"Hirsh","year":"2007","journal-title":"Circulation"},{"key":"R110-13-20210902","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/35038119","article-title":"Structure of a serpin-protease complex shows inhibition by deformation.","volume":"407","author":"Huntington","year":"2000","journal-title":"Nature"},{"key":"R111-13-20210902","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0038-1653794","article-title":"Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.","volume":"73","author":"Wolzt","year":"1995","journal-title":"Thromb Haemost"},{"key":"R112-13-20210902","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0049-3848(02)00387-0","article-title":"Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians.","volume":"108","author":"Douketis","year":"2002","journal-title":"Thromb Res"},{"key":"R113-13-20210902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.jvca.2004.11.002","article-title":"Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients.","volume":"19","author":"McDonald","year":"2005","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R114-13-20210902","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1378\/chest.125.3.856","article-title":"Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.","volume":"125","author":"Thorevska","year":"2004","journal-title":"Chest"},{"key":"R115-13-20210902","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-5223(20)31420-3","article-title":"The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.","volume":"102","author":"Dietrich","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R116-13-20210902","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0003-4975(94)91359-5","article-title":"Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping.","volume":"57","author":"Staples","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"R117-13-20210902","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1213\/01.ANE.0000134685.75813.EB","article-title":"The effects of argatroban on thrombin generation and hemostatic activation in vitro.","volume":"99","author":"Tanaka","year":"2004","journal-title":"Anesth Analg"},{"key":"R118-13-20210902","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1537-2995.1992.32692367206.x","article-title":"Antithrombin III: physiology, deficiency, and replacement therapy.","volume":"32","author":"Menache","year":"1992","journal-title":"Transfusion"},{"key":"R119-13-20210902","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood-2007-01-067116","article-title":"Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.","volume":"110","author":"Lambert","year":"2007","journal-title":"Blood"},{"key":"R120-13-20210902","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1161\/01.CIR.0000147537.72829.1B","article-title":"Heparin-induced thrombocytopenia: diagnosis and management.","volume":"110","author":"Warkentin","year":"2004","journal-title":"Circulation"},{"key":"R121-13-20210902","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood-2003-07-2229","article-title":"Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin.","volume":"103","author":"Eichler","year":"2004","journal-title":"Blood"},{"key":"R122-13-20210902","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","article-title":"Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.","volume":"84","author":"Warkentin","year":"1994","journal-title":"Blood"},{"key":"R123-13-20210902","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJM200008173430718","article-title":"Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.","volume":"343","author":"Potzsch","year":"2000","journal-title":"New Engl J Med"},{"key":"R124-13-20210902","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1055\/s-0038-1657729","article-title":"The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.","volume":"78","author":"Elg","year":"1997","journal-title":"Thromb Haemost"},{"key":"R125-13-20210902","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","article-title":"Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.","volume":"101","author":"Okamoto","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"R126-13-20210902","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"R127-13-20210902","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-0038-1648875","article-title":"Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.","volume":"72","author":"Berry","year":"1994","journal-title":"Thromb Haemost"},{"key":"R128-13-20210902","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.V77.5.1006.1006","article-title":"Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.","volume":"77","author":"Kelly","year":"1991","journal-title":"Blood"},{"key":"R129-13-20210902","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1073\/pnas.89.13.6040","article-title":"Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.","volume":"89","author":"Kelly","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"R130-13-20210902","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2004-02-0621","article-title":"Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.","volume":"104","author":"Lubenow","year":"2004","journal-title":"Blood"},{"key":"R131-13-20210902","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","article-title":"The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.","volume":"20","author":"Swan","year":"2000","journal-title":"Pharmacotherapy"},{"key":"R132-13-20210902","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH05-03-0154","article-title":"Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.","volume":"94","author":"Warkentin","year":"2005","journal-title":"Thromb Haemost"},{"key":"R133-13-20210902","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/ALN.0b013e31817885b7","article-title":"Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin.","volume":"109","author":"Molinaro","year":"2008","journal-title":"Anesthesiology"},{"key":"R134-13-20210902","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/MBC.0b013e3282a167a7","article-title":"Low-dose tenecteplase during cardiopulmonary resuscitation due to massive pulmonary embolism: a case report and review of previously reported cases.","volume":"18","author":"Hefer","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R135-13-20210902","doi-asserted-by":"crossref","first-page":"483S","DOI":"10.1378\/chest.126.3_suppl.483S","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.","volume":"126","author":"Albers","year":"2004","journal-title":"Chest"},{"key":"R136-13-20210902","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.mcna.2007.03.008","article-title":"Primary percutaneous coronary intervention in acute myocardial infarction.","volume":"91","author":"Singh","year":"2007","journal-title":"Med Clin North Am"},{"key":"R137-13-20210902","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ccd.21079","article-title":"Catheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review.","volume":"70","author":"Issa","year":"2007","journal-title":"Catheter Cardiovasc Intervent"},{"key":"R138-13-20210902","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/S0021-9258(19)81051-7","article-title":"Kinetics of the activation of plasminogen by human tissue plasminogen activator.","volume":"257","author":"Hoylaerts","year":"1982","journal-title":"Role of fibrin. J Biol Chem"},{"key":"R139-13-20210902","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1046\/j.1538-7836.2003.00279.x","article-title":"Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.","volume":"1","author":"Juhan-Vague","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R140-13-20210902","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1432-1033.1978.tb12360.x","article-title":"On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin.","volume":"87","author":"Wiman","year":"1978","journal-title":"Eur J Biochem"},{"key":"R141-13-20210902","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1172\/JCI109671","article-title":"Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.","volume":"65","author":"Sakata","year":"1980","journal-title":"J Clin Invest"},{"key":"R142-13-20210902","doi-asserted-by":"crossref","first-page":"27220","DOI":"10.1074\/jbc.273.42.27220","article-title":"Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin.","volume":"273","author":"Valnickova","year":"1998","journal-title":"J Biol Chem"},{"key":"R143-13-20210902","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V88.10.3815.bloodjournal88103815","article-title":"Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.","volume":"88","author":"Broze","year":"1996","journal-title":"Blood"},{"key":"R144-13-20210902","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1161\/01.ATV.0000244680.14653.9a","article-title":"Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis.","volume":"26","author":"Mosnier","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R145-13-20210902","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MBC.0b013e3282f41e6d","article-title":"Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.","volume":"19","author":"Taketomi","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R146-13-20210902","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1182\/blood.V82.8.2433.2433","article-title":"Competition between plasminogen and tissue plasminogen activator for cellular binding sites.","volume":"82","author":"Felez","year":"1993","journal-title":"Blood"},{"key":"R147-13-20210902","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0038-1657557","article-title":"Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.","volume":"78","author":"Nesheim","year":"1997","journal-title":"Thromb Haemost"},{"key":"R148-13-20210902","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(83)91216-3","article-title":"Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.","volume":"2","author":"Branson","year":"1983","journal-title":"Lancet"},{"key":"R149-13-20210902","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis.","volume":"344","author":"Bernard","year":"2001","journal-title":"New Engl J Med"},{"key":"R150-13-20210902","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00003246-200301000-00002","article-title":"Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.","volume":"31","author":"Ely","year":"2003","journal-title":"Crit Care Med"},{"key":"R151-13-20210902","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMra067742","article-title":"Prevention and treatment of major blood loss.","volume":"356","author":"Mannucci","year":"2007","journal-title":"New Engl J Med"},{"key":"R152-13-20210902","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH06-07-0408","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system.","volume":"96","author":"Hemker","year":"2006","journal-title":"Thromb Haemost"},{"key":"R153-13-20210902","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00000542-200205000-00011","article-title":"Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study.","volume":"96","author":"Levy","year":"2002","journal-title":"Anesthesiology"}],"container-title":["Anesthesia & Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000539-200905000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:12:04Z","timestamp":1786111924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-200905000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":153,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e31819bcc9c","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}